Blueprint Medicines(BPMC) - 2022 Q4 - Earnings Call Transcript

At this time, I'd like to turn over to Jenna Cohen, Head of Investor Relations at Blueprint Medicines. Please proceed. Jenna Cohen Today on our call, Kate Haviland, our Chief Executive Officer, will provide a perspective on Blueprint's 2022 accomplishments and how that positions us to continue to grow and drive value in 2023. Philina Lee, our Chief Commercial Officer, will review AYVAKIT's performance and our upcoming opportunity to expand the label and treat many more patients with SM. Christy Rossi, Chief ...